Synergistic Combinations for Neurokinin-3 Receptor-Related Disorders

A novel system integrating curcumin compositions with AI, IoT, blockchain, and other technologies to treat neurokinin-3 receptor-related disorders, offering personalized and optimized treatment outcomes.

The original patent identified curcumin compositions as potent NK3 antagonists, but it lacked integration with other technologies to enhance treatment efficacy and patient outcomes. This inventive concept addresses this limitation by combining curcumin compositions with AI, IoT, blockchain, and other technologies to create a more powerful system for treating neurokinin-3 receptor-related disorders.

The inventive concept comprises a curcumin composition, which may be combined with other natural ingredients, such as green tea extract and phycocyanin, in synergistic ratios. This composition is integrated with AI-powered diagnostic tools to identify patients with high neurokinin-3 receptor expression, blockchain-based platforms for secure data storage and tracking, and IoT sensors for real-time monitoring of neurokinin-3 receptor activity. Additionally, genomic sequencing and machine learning algorithms are used to personalize treatment and optimize curcumin composition formulations. The system provides a controlled release profile of the composition through nanoparticle encapsulation, ensuring targeted and efficient treatment.

The new claims introduce a synergistic combination of curcumin compositions with AI, IoT, blockchain, and other technologies, which is not obvious from the original patent. The integration of these distinct technologies creates a novel system that provides personalized and optimized treatment outcomes for neurokinin-3 receptor-related disorders.

Alternative embodiments may include varying the ratio of curcumin composition to other natural ingredients, using different AI algorithms for diagnostic and predictive purposes, or incorporating other technologies such as nanotechnology or 3D printing to enhance treatment efficacy. Variations may also include using the system for treating other diseases or disorders related to neurokinin-3 receptor expression.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine, AI-assisted diagnostics, and IoT-enabled healthcare. The target market includes patients with neurokinin-3 receptor-related disorders, such as anxiety, depression, and chronic pain, as well as healthcare providers and pharmaceutical companies seeking to develop more effective treatment options.